Achilles Therapeutics plc
| NASDAQ: ACHL | - / - / - |
| 0.8600 | -0.0200 | -2.27% | Vol 49.29K | 1Y Perf -63.18% |
| Oct 4th, 2023 15:59 DELAYED |
| BID | 0.8410 | ASK | 0.8600 | ||
| Open | 0.8600 | Previous Close | 0.8800 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 10.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 1.06K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 6.26 | Earnings Rating | — | |
| Market Cap | 35.20M | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.08 | Standard Deviation | 0.19 | |
| Beta | 0.87 |
Today's Price Range 0.83500.8800 | 52W Range 0.75002.51 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.70% | ||
| 1 Month | -7.37% | ||
| 3 Months | -6.38% | ||
| 6 Months | -8.33% | ||
| 1 Year | -63.18% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -28.35 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -25.78 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -24.66 | |||
Return on invested Capital Q | -5.50 | |||
Return on invested Capital Y | -24.10 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.70 | ||||
| 0.24 | ||||
| - | ||||
| - | ||||
| -1.20 | ||||
| -1.55 | ||||
| 0.24 | ||||
| 4.95 | ||||
| -122 594 000.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 9.40 | ||||
| 10.40 | ||||
| 0.02 | ||||
| 0.04 | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.40 | -0.42 | -5.00 |
| Q01 2023 | -0.41 | -0.44 | -7.32 |
| Q04 2022 | -0.42 | -0.61 | -45.24 |
| Q03 2022 | -0.55 | -0.32 | 41.82 |
| Q02 2022 | -0.57 | -0.44 | 22.81 |
| Q01 2022 | -0.51 | -0.45 | 11.76 |
| Q04 2021 | -0.39 | -0.45 | -15.38 |
| Q03 2021 | -0.49 | -0.34 | 30.61 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 14th Nov 2023 |
| Estimated EPS Next Report | -0.38 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 49.29K |
| Shares Outstanding | 40.93K |
| Shares Float | 17.85M |
| Trades Count | 165 |
| Dollar Volume | 41.92K |
| Avg. Volume | 58.06K |
| Avg. Weekly Volume | 47.26K |
| Avg. Monthly Volume | 49.60K |
| Avg. Quarterly Volume | 77.33K |
Achilles Therapeutics plc (NASDAQ: ACHL) stock closed at 0.88 per share at the end of the most recent trading day (a -3.3% change compared to the prior day closing price) with a volume of 29.44K shares and market capitalization of 35.20M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the industry, sector and employs 0 people. Achilles Therapeutics plc CEO is .
The one-year performance of Achilles Therapeutics plc stock is -63.18%, while year-to-date (YTD) performance is -2.22%. ACHL stock has a five-year performance of %. Its 52-week range is between 0.75 and 2.5069, which gives ACHL stock a 52-week price range ratio of 6.26%
Achilles Therapeutics plc currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 0.24, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -25.78%, a ROC of -24.66% and a ROE of -28.35%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Achilles Therapeutics plc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. Achilles Therapeutics plc’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Achilles Therapeutics plc is Strong Buy (1), with a target price of $10, which is +1 062.79% compared to the current price. The earnings rating for Achilles Therapeutics plc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Achilles Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Achilles Therapeutics plc has a Sell technical analysis rating based on Technical Indicators (ADX : 20.24, ATR14 : 0.05, CCI20 : -36.79, Chaikin Money Flow : 0.01, MACD : -0.01, Money Flow Index : 66.12, ROC : -0.85, RSI : 45.55, STOCH (14,3) : 39.49, STOCH RSI : 0.00, UO : 64.38, Williams %R : -60.51), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Achilles Therapeutics plc in the last 12-months were:
